Ursula A. Matulonis, MD
Ursula A. Matulonis, MD, chief of the gynecological oncology division at Dana Farber Cancer Institute, spoke with Healio about developments in PARP inhibitors for ovarian cancer, unmet needs among patients with ovarian cancer and continuing momentum in drug development and immunotherapy.
In this video, Matulonis discusses:
- the role of PARP inhibitors in platinum sensitivity, clinical biomarkers and synthetic lethality;
- continuing momentum in drug development and immunotherapy;
- how new drugs are changing the outlook of ovarian cancer;
- awareness of idiosyncratic toxicity in PARP inhibitors;
- potential barriers to treatment; and
- how drug literature may impact patient wellness.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.